Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Allogene Therapeutics (ALLO) Leases (2019 - 2025)

Allogene Therapeutics' Leases history spans 7 years, with the latest figure at $40.9 million for Q3 2025.

  • For Q3 2025, Leases rose 224.88% year-over-year to $40.9 million; the TTM value through Sep 2025 reached $40.9 million, up 224.88%, while the annual FY2024 figure was $45.2 million, 29.04% down from the prior year.
  • Leases for Q3 2025 was $40.9 million at Allogene Therapeutics, down from $42.0 million in the prior quarter.
  • Across five years, Leases topped out at $86.8 million in Q2 2022 and bottomed at $7.5 million in Q2 2024.
  • The 5-year median for Leases is $57.1 million (2022), against an average of $55.3 million.
  • The largest annual shift saw Leases skyrocketed 40089.0% in 2021 before it plummeted 90.66% in 2024.
  • A 5-year view of Leases shows it stood at $58.0 million in 2021, then soared by 44.05% to $83.6 million in 2022, then fell by 23.79% to $63.7 million in 2023, then dropped by 29.04% to $45.2 million in 2024, then dropped by 9.45% to $40.9 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Leases are $40.9 million (Q3 2025), $42.0 million (Q2 2025), and $44.1 million (Q1 2025).